Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Clotet
Bonaventura
B
Fundaciò IrsiCaixa Laboratori de Retrovirologia, and HIV Unit Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
Negredo
Eugenia
E
Girard
Pierre Marie
PM
Youle
Mike
M
Neubacher
Dietmar
D
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D011753:Pyrones / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D063065:Organophosphonates; D011725:Pyridines; D011753:Pyrones; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine; D019438:Ritonavir; C107201:tipranavir